Back to Freepaper Session

A first step towards a drug-eluting intraocular lens

Session Details

Session Title: New IOLs

Session Date/Time: Tuesday 08/10/2013 | 16:30-18:15

Paper Time: 17:11

Venue: Elicium 1 (First Floor)

First Author: : L.Lamprogiannis GREECE

Co Author(s): :    V. Karagkiozaki   S. Logothetidis   M. Gioti   A. Karamitsos   S. Dimitrakos   I.

Abstract Details

Purpose:

The development, characterization and drug release study of one-layer and two-layers thin films based on organic polymers and dexamethasone in order to examine their applicability on intraocular lenses and their function as intraocular drug delivery systems

Setting:

Anterior Eye Department, 2nd University Ophthalmology Clinic, Aristotle University of Thessaloniki, Papageorgiou Hospital, Greece -- Laboratory for Thin Films, Nanosystems and Nanometrology, Physics Department of Aristotle University of Thessaloniki, Greece

Methods:

Four groups of thin films were prepared by the method of spin coating on silicon substrate: group A, consisting of two layers of in a 2:1 ratio with dexamethasone, group B with two layers in a 3:1 ratio with dexamethasone, group C with one layer in a 2:1 ratio with dexamethasone and group D with one layer in a 3:1 ratio with dexamethasone. Organic polymers served as matrix for all the films. The films were studied with the use of AFM and ellipsometry. Release rate of dexamethasone was studied for a period of ten weeks.

Results:

Conclusions have been reached in relevance to the surface structure and roughness of the films. Groups A and B demonstrated the formation of aggregates of dexamethasone. The monolayer films of groups C and D formed nanopores, in agreement with previous findings. The ellipsometry study showed transparent samples. The study of drug release demonstrated a smooth release for the first 6 weeks.

Conclusions:

The films exhibited properties (transparency, release duration, release curve) that serve the purpose of using them as systems for intraocular drug delivery. Further research includes development of the drug delivery system directly on the surface of the IOL.

Financial Interest:

NONE